Latest Licensing Agreements News

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

PARKD Limited has clinched exclusive national rights to prefabricate key modular building components from Fielders, positioning itself to capitalize on booming construction sectors like data centres and self-storage across Australia.

Jumbo Interactive has inked a five-year SaaS agreement to power RSL Queensland’s Dream Home Art Union lottery, Australia’s largest prize home lottery. This deal marks a strategic shift from reseller to platform partner, reinforcing Jumbo’s leadership in the charity lottery sector.

Livium Ltd has inked a term sheet with the University of Melbourne to exclusively commercialise innovative microwave technology for rare earth elements extraction, promising high recovery rates and major energy savings.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

ClearVue Technologies reported a striking 553% revenue increase to nearly $250,000 in FY2025, alongside a 7% reduction in net loss, driven by strategic partnerships and global project wins.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.